Verluma Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to advancements in nuclear imaging technologies, increased prevalence of colorectal and solid tumors, improved availability of radiopharmaceuticals, expansion of oncology diagnostic infrastructure, growing clinical acceptance of targeted imaging agents.

The growth in the forecast period can be attributed to growing demand for personalized cancer diagnostics, rising investments in nuclear medicine facilities, expansion of companion diagnostics in oncology, increased use of molecular imaging in cancer staging, ongoing innovation in radiolabeled antibody fragments. Major trends in the forecast period include growing adoption of targeted radiolabeled diagnostics, increasing use of cea-targeted imaging agents, rising demand for early cancer detection tools, expansion of nuclear medicine imaging applications, strengthening integration of precision oncology diagnostics.

The increasing incidence of cancer is expected to drive the growth of the Verluma market in the coming years. Cancer is a group of diseases marked by the uncontrolled growth and spread of abnormal cells, which can invade nearby tissues and potentially metastasize through the blood and lymphatic systems. The rise in cancer cases is influenced by factors such as aging populations, lifestyle changes, and the global spread of risk factors. Verluma is a therapeutic device that uses advanced technologies, such as electromagnetic fields or other non-invasive methods, to potentially assist in cancer treatment by targeting and disrupting cancer cell growth, promoting healing, and supporting the body’s response to other therapies. For example, according to the American Cancer Society, a US-based non-profit organization, around 313,510 new breast cancer cases were diagnosed in 2024, up from 300,590 cases in 2023. Therefore, the rising incidence of cancer is driving growth in the Verluma market.

The rise in healthcare expenditure is also expected to support the growth of the Verluma market. Healthcare expenditure refers to the total financial resources spent on medical services, hospital care, pharmaceuticals, infrastructure, and preventive healthcare. The increase in healthcare spending is attributed to aging populations, the growing prevalence of chronic diseases, advancements in medical technology, and higher demand for healthcare services. Increased healthcare spending benefits Verluma by driving demand for advanced healthcare technologies that improve patient outcomes and operational efficiencies as providers invest in innovative tools. For instance, according to the Office for National Statistics, a UK-based government agency, provisional estimates show UK healthcare spending reached £317 billion in 2024, growing 6.5% nominally and 2.4% in real terms from 2023, with total long-term care expenditure rising 3.1% in real terms, primarily due to increased government funding. Therefore, rising healthcare expenditure is driving growth in the Verluma market.

The increasing demand for diagnostic imaging procedures is expected to propel the growth of the Verluma market. Diagnostic imaging involves medical techniques used to create visual representations of the body’s interior for clinical evaluation and medical intervention. The demand for imaging procedures is rising due to the growing prevalence of chronic diseases, an emphasis on early detection and preventive care, and greater access to healthcare. Verluma enhances diagnostic imaging by improving image quality through advanced algorithms, enabling more precise detection and analysis of medical conditions and better patient outcomes. For example, according to the National Health Service, a UK-based government department, England recorded 45 million imaging tests in the year ending March 2023, reflecting a 2.2% increase from 44 million in 2022. Therefore, the growing demand for diagnostic imaging procedures is driving the growth of the Verluma market.

Major companies operating in the verluma market are Boehringer Ingelheim International GmbH.

North America was the largest region in the verluma market in 2025. The regions covered in the verluma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the verluma market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the verluma market by increasing costs of imported radioisotopes, imaging-grade antibodies, specialized labeling equipment, and radiation-shielded packaging materials. Diagnostic centers and hospitals in North America and Europe are most affected due to dependence on imported nuclear medicine inputs, while Asia-Pacific faces logistical and cost challenges in radiopharmaceutical supply chains. These tariffs are increasing operational expenses and limiting flexible sourcing of imaging agents. However, they are also promoting regional isotope production, domestic radiopharmaceutical manufacturing, and greater investment in localized nuclear medicine infrastructure.

The verluma market research report is one of a series of new reports that provides verluma market statistics, including verluma industry global market size, regional shares, competitors with a verluma market share, detailed verluma market segments, market trends and opportunities, and any further data you may need to thrive in the verluma industry. This verluma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Verluma is a radiolabeled monoclonal antibody fragment used in nuclear medicine to target carcinoembryonic antigen (CEA), a protein frequently overexpressed in tumors. It aids in detecting and staging cancers, such as colorectal cancer, by binding to CEA-expressing tumor cells, enabling visualization through imaging techniques like SPECT.

The primary indications for Verluma are cancer and non-cancer conditions. Cancer comprises diseases characterized by uncontrolled cell growth with the potential to spread, and treatments like Verluma target specific cancer cells to reduce tumor growth and improve patient outcomes. Verluma is distributed through hospital pharmacies and online pharmacies and serves adult and elderly patients.

The verluma market consists of sales of verluma injection and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.